OR WAIT null SECS
Legislation has hampered cross-border drug importation and limited choice.
Innovation in medicine offers great hope for improving lives, and pharmaceutical research companies are making every possible effort to fight life-threatening diseases to ensure people's health. Unfortunately, consumers do not always have affordable access to prescription drugs that can help treat their medical conditions.
In the United States, 15 to 25% of the population has reported not filling a prescription on time and/or reducing a prescribed dosage due to cost (1, 2). Although the US Medicare Prescription Drug, Improvement, and Modernization Act (MMA), enacted in 2003, provided the largest overhaul to date of America's public health program, many beneficiaries still face challenges in getting healthcare and medication benefits (3, 4). And while the Affordable Care Act of 2010 increased benefits and access for Medicare beneficiaries, many of the legislation's overhauls have yet to be implemented.
As a result, many Americans continue to purchase drugs outside US borders at a lesser cost. Many of the drugs bought abroad were actually approved by FDA, manufactured in the US, and sold to other countries. Canada, in particular, is a prime recipient of such products. When these drugs are sold to Americans who bring them back into the US, they become illegally imported and hence are referred to as "reimported drugs."
Brand-name drugs that are manufactured in foreign countries, on the other hand, can be legally imported into the US if they comply with the Food, Drug, and Cosmetic Act (FD&C Act). This process is often referred to as "drug importation." Under the FD&C Act, any entity that intends to import prescription drugs into the US must ensure that the drug products are FDA-approved, meet all US manufacturing and labeling requirements, and do not violate the FD&C Act's import and and export section (5).
Although there is always some concern about the safety and quality of imported drugs, reimported drugs, in particular, carry more potential for being illegitimate and unsafe. Specifically, they may lack proper authentication, originate from unreliable outlets, be expired or contaminated, and lack correct dose information or directions for use. FDA has traced multiple violations of drug reimportation laws and found that most reimported drugs do not include the required label information.
Nevertheless, for many US residents, financial concerns outweigh the risks of prescription drug reimportation. There is a need, therefore, to prevent consumers from falling prey to online marketing of unsafe drugs.
In 2000, the US Congress passed the Medicine Equity and Drug Safety (MEDS) Act to provide Americans with a legal means to obtain low-cost prescription drugs from industrialized countries. Later, MMA sought to prevent Americans from seeking less expensive drugs from Canada by authorizing drug reimportation, but providing veto authority to the US Secretary of Health and Human Services over its implementation, and to date, the secretary has used this veto power (6). Thus, MMA has not enabled safe drug reimportation.
In 2009, US Senator Byron Dorgan (D-ND) pushed to include drug importation in President Obama's healthcare reform bill. Dorgan's legislation, called the Pharmaceutical Market Access and Drug Safety Act of 2009 (PMADS), was designed to establish a system for American consumers to import low-cost prescription drugs safely (7). The PMADS Act was designed to legalize reimportation as well. The amendment is still in legislative process.
The President's Fiscal Year 2010 budget request included $5 million to allow FDA to begin working with various stakeholders to develop policy options related to drug importation (8).
FY2011 budget provides $2.5 billion in budget authority and $4 billion in total program resources for FDA in this regard. The funds include efforts to bring more safe, effective, and low-cost generic drugs (including follow-on biologics) to the US market (9). These activities will ultimately help to make safe drugs more affordable and readily available to American consumers.
But in the immediate future, reimportation remains a controversial issue. Making reimportation legal may not bring long-term benefits to the US market because of already mentioned concerns over safety. Reimportation also could reduce companies' revenue and thereby deplete funding for new-drug research and development.
American consumers will benefit most when drug prices are controlled at a global level. The authors propose the formation of an international body of pharmaceutical leaders to monitor the flow of pharmaceuticals across borders and to regulate prices internationally. (FDA and other regulatory agencies do not regulate prices.) An international consortium of pharmaceutical companies could work to find common ground with consumers on drug pricing internationally, which could reduce drug reimportation.
An active dialogue between company representatives and government representing American consumers also is necessary to keep drug reimportation off the table. Educating consumers about the risks of bringing drugs into the country illegaly is crucial, as is discussing alternatives to low-cost products.
Om V. Singh, PhD, is assistant professor in the Division of Biological and Health Sciences at the University of Pittsburgh in Bradford, PA, firstname.lastname@example.org. Thomas E. Colonna, PhD, is associate director of the Bioscience Regulatory Affairs Program in the Zanvyl Krieger School of Arts and Sciences at Johns Hopkins University in Washington, DC, email@example.com.
1. T.S. Rector and P.J. Venus, Health Aff. 23 (2004) 213–222.
2. D.G. Safran et al., Health Aff. Supp. web exclusive (2002), pp. W253–68.
3. Public Law 108-173, Medicare Prescription Drug, Improvement, and Modernization Act of 2003.
4. HHS, Medicare Modernization Act Update–Overview, www.cms.gov/PrescriptionDrugCovGenIn/01_Overview.asp, accessed Jan. 5, 2011.
5. HHS, Report on Prescription Drug Importation (December 2004), http://archive.hhs.gov/importtaskforce/Report1220.pdf, accessed Dec. 1, 2010.
6. American Progress, "Prescription Drug Reimportation: The Law and Its Problems," www.americanprogress.org/kf/bgreimp.pdf, accessed Dec. 1, 2010.
7. US Congress, H.R. 1298: Pharmaceutical Market Access and Drug Safety Act of 2009, www.govtrack.us/congress/bill.xpd?bill=h111-1298, accessed Jan. 5, 2011.
8. HHS, FY2010 Budget in Brief, http://dhhs.gov/asfr/ob/docbudget/2010budgetinbrief.pdf, accessed Dec. 20 2010.
9. HHS, FY2010 Budget, www.gpoaccess.gov/usbudget/fy11/pdf/budget/health.pdf, accessed Dec. 20, 2010.